Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 2, 2018, Pages

  Kawaguchi, Nao ^a   Katsube, Takayuki ^a   Echols, Roger ^b   Wajima, Toshihiro ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b Infectious Disease Drug Development Consulting LLC   (United States)

Author keywords

Acute uncomplicated pyelonephritis; Augmented renal function; Cefiderocol; Cephalosporin; Complicated urinary tract infection; Pharmacokinetics; Population pharmacokinetics; Renal function; Siderophore

Indexed keywords

CEFIDEROCOL; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; CREATININE; SIDEROPHORE;

ACUTE PYELONEPHRITIS; ADULT; AGED; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; URINARY TRACT INFECTION; ACUTE DISEASE; ADOLESCENT; BLOOD; BODY WEIGHT; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; GLOMERULUS FILTRATION RATE; GRAM NEGATIVE INFECTION; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PYELONEPHRITIS; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; VERY ELDERLY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BODY WEIGHT; CASE-CONTROL STUDIES; CEPHALOSPORINS; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PYELONEPHRITIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; SIDEROPHORES; URINARY TRACT INFECTIONS;

EID: 85041077898     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01391-17     Document Type: Article

References (24)

1. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of S-649266, a catechol substituted siderophore cephalosporin, when tested against non-fermenting gram-negative bacteria. J Antimicrob Chemother 71:670–677. https://doi.org/10.1093/jac/dkv402.
2. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2015. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729–734. https://doi.org/10.1128/AAC.01695-15.
3. Ito A, Toba S, Nishikawa T, Oota M, Kanazawa S, Fukuhara N, Yamaguchi T, Nakamura R, Tsuji M, Yamano Y. 2015. S-649266, a novel siderophore cephalosporin: binding affinity to PBP and in vitro bactericidal activity, abstr ECCMID-1871. Abstr 25th Eur Congr Clin Microbiol Infect Dis (ECCMID).
4. Nakamura R, Toba S, Tsuji M, Yamano Y, Shimada J. 2014. A novel siderophore cephalosporin. IV. In vivo efficacy in various murine infection models, abstr F-1558. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
5. Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. 2014. A novel siderophore cephalosporin. V. Pharmacodynamic assessment in murine thigh infection models, abstr F-1559. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
6. Horiyama T, Toba S, Nakamura R, Tsuji M, Yamano Y, Shimada J. 2014. A novel siderophore cephalosporin. VI. Magnitude of PK/PD parameter required for efficacy in murine lung infection model, abstr F-1560. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
7. Horiyama T, Toba S, Nakamura R, Tsuji M, Yamano Y, Shimada J. 2014. A novel siderophore cephalosporin. VII. Magnitude of PK/PD parameter required for efficacy in murine thigh infection model, abstr F-1561. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
8. Craig WA. 1995. Interrelationship between pharmacokinetics and phar-macodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22:89–96. https://doi.org/10.1016/0732-8893(95)00053-D.
9. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–12. https://doi.org/10.1086/516284.
10. Shimada J, Saisho Y, Katsube T, White S, Fukase H. 2014. S-649266, a novel siderophore cephalosporin for Gram negative bacterial infections: pharmacokinetics, safety and tolerability in healthy subjects, abstr F-1564. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
11. Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. 2017. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol 57:584–591. https://doi.org/10.1002/jcph.841.
12. Katsube T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R. 2017. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother 61:e01381-16. https://doi .org/10.1128/AAC.01381-16.
13. Portsmouth S, Veenhuyzen D, Echols R, Machida M, Arjona Ferreira JC, Ariyasu M, Nagata T. 2017. Cefiderocol compared with imipenem/ cilastatin in the treatment of adults with complicated urinary tract infections with or without pyelonephritis or acute uncomplicated pyelonephritis: results from a multicenter, double-blind, randomized study (APEKS-cUTI), abstr ECCMD-7582. Abstr 27th Eur Congr Clin Microbiol Infect Dis (ECCMID).
14. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration. 2006. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247–254. https://doi.org/10.7326/0003-4819-145-4-200608150-00004.
15. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. 2009. Collaborators Developing the Japanese Equation for Estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992. https://doi.org/10.1053/j.ajkd.2008.12.034.
16. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41. https://doi.org/10.1159/000180580.
17. Lin J, Knight EL, Hogan ML, Singh AK. 2003. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 14:2573–2580. https://doi.org/10.1097/01.ASN.0000088721.98173.4B.
18. Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang YL, Schmid CH, Levey AS, Chronic Kidney Disease Epidemiology Collaboration. 2009. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 54:33–42. https://doi.org/10.1053/j.ajkd.2009.03.008.
19. Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, Lipman J. 2011. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 15:R139. https://doi.org/10.1186/cc10262.
20. Chandorkar G, Xiao A, Mouksassi MS, Hershberger E, Krishna G. 2015. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol 55:230–239. https://doi.org/10.1002/jcph.395.
21. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143–151. https://doi.org/10.1208/s12248-011-9255-z.
22. Beal SL, Sheiner LB, Boeckmann AJ. 1989-2006. NONMEM users guide. Icon Development Solutions, Ellicott City, MD.
23. Lindbom L, Pihlgren P, Jonsson EN. 2005. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241–257. https://doi.org/10.1016/j.cmpb.2005.04.005.
24. R Core Team. 2013. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.